Ose Immunotherapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Ose Immunotherapeutics Stock-Based Compensation Growth & History (OSE)
Ose Immunotherapeutics's stock-based compensation was €1.9M for fiscal 2025.
View full Ose Immunotherapeutics company overviewOse Immunotherapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €1.9M | −€813,000 | −29.85% |
| 2024 | 2024-12-31 | €2.7M | €690,000 | +33.92% |
| 2023 | 2023-12-31 | €2.0M | −€1.1M | −35.02% |
| 2022 | 2022-12-31 | €3.1M | −€643,000 | −17.04% |
| 2021 | 2021-12-31 | €3.8M | €1.5M | +65.27% |
| 2020 | 2020-12-31 | €2.3M | — | — |
Ose Immunotherapeutics stock-based compensation trends
Over the last five fiscal years, Ose Immunotherapeutics's stock-based compensation decreased from €2.3M to €1.9M, a change of −€372,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
reported stock-based compensation
TickerStat standardizes share-based compensation reported in company official filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ose Immunotherapeutics source filings ↗